CEP-32496 is a small molecule BRAF kinase inhibitor being developed by our partner, Cephalon.
Role of BRAF in Oncology. Mutations in the BRAF gene are among the most commonly identified mutations in human cancers including melanoma, thyroid, colon, ovarian and lung cancers.
CEP-32496 Development. CEP-32496 shows significant potential in BRAF mutant cancers because it targets mutations in BRAF in addition to related family members, thereby maximizing inhibition of the pathway that drives the disease. CEP-32496 is a very potent inhibitor in BRAF-dependant tumor cells in animal models and is currently in IND-enabling studies.